As MAPK pathway inhibitors, in particular the MEK inhibitor Trametinib has previously been shown to have limited efficacy in ALK-aberrant NB due to activation of pro-survival feedback signaling through Akt/mTORc37, we decided to investigate an inhibitor of NRAS activity, a protein upstream of both PI 3-Kinase and MEK78. This evidence concerns the gene MAP2K7 and neuroblastoma.